GENB Generate Biomedicines, Inc.
Company Analysis
Latest News
🟢 Generate Biomedicines is trading 11.45% up today amid a broad risk-on rebound
Generate Biomedicines is trading 11.45% up at $17.48, moving with a broad risk-on rebound rather than a clearly disclosed company-specific catalyst. - Biotech...
🟢 Generate Biomedicines is trading 10.01% up today as biotech joins broader risk-on rebound
Generate Biomedicines is trading 10.01% up now at $17.35 as biotech shares strengthen alongside a broader risk-on market rebound. - Biotech is up 2.55%, while...
🟢 Generate Biomedicines is trading 7.53% up today as biotech sector gains 2.55%
Generate Biomedicines is trading at $16.80, up 7.53% now, most likely reflecting biotech-sector strength and improved risk appetite. • Broader markets are...
🟢 Generate Biomedicines is trading 4.3% up today after Morgan Stanley conference highlighted AI-driven pipeline
Generate Biomedicines is trading 4.26% up at $16.39 after management presented at the Morgan Stanley Global Healthcare Conference on September 14, 2026. -...
🔴 Generate Biomedicines is trading 4.31% down today as Brent crude rose above $100
Generate Biomedicines is trading 4.31% down at $15.21 amid a broad market selloff as Brent crude rose above $100 amid intensifying U.S.-Iran tensions. - The...
🔴 Generate Biomedicines is trading 4.27% down today
Generate Biomedicines is trading 4.27% down at $15.69, with no clear company-specific negative catalyst identified for September 8, 2026. - The company...
🟢 Generate Biomedicines is trading 5.3% up today on positive GB-0895 asthma data
Generate Biomedicines is trading $16.63 (+5.32%) on September 2, 2026, after H.C. Wainwright raised its price target to $30 from $25 while maintaining a Buy...
🟢 Generate Biomedicines is trading 4.13% up today after H.C. Wainwright raised target to $30
Generate Biomedicines is trading 4.13% up at $15.90, outperforming a biotechnology sector down 4.24% on September 1, 2026, after H.C. Wainwright raised its...
Generate Biomedicines Target Hiked to $30, Following Positive Asthma Trial Results
H.C. Wainwright reiterated its Buy rating on Generate Biomedicines. The firm increased its price target to $30 from $25. The adjustment follows the early...
🔴 Generate Biomedicines falls 4.1% — Biotech Sector Declines Amid Fed Rate Hike Fears
With Biotech (XBI) down 2.3%, this looks like a sector-led move rather than a company-specific surprise. The biotech sector, as measured by the XBI ETF, fell...
🟢 Generate Biomedicines is trading 4.3% up today as Nasdaq Composite gains 1.09%
Generate Biomedicines is trading 4.3% up at $16.84 as the Nasdaq Composite gains 1.09% and technology and growth stocks lead a modest risk-on session. -...
🟢 Generate Biomedicines is trading 5% up in pre-market as Nasdaq Composite rises 0.94%
Generate Biomedicines is trading 4.89% up at $16.93, with the broader market supportive as the Nasdaq Composite rises 0.94%. - Shares declined 20.80% on...
🔴 Generate Biomedicines is trading 14.03% down today amid possible profit-taking or rally reversal
Generate Biomedicines is trading 14.03% down now at $17.52, with profit-taking or rally reversal suggested but unconfirmed. - It gained 15.01% to $20.38 on...
GENB Discloses Positive GB-0895 Data Supporting 6-Month Dosing for Asthma & COPD
Generate Biomedicines disclosed positive Phase 1 clinical trial data for its drug candidate, GB-0895, after posters for the European Respiratory Society...
🟢 Generate Biomedicines up 5% in pre-market ahead of lock-up expiration and upcoming clinical data
Generate Biomedicines is trading 5.25% up at $21.45, driven by anticipation of its August 26 post-IPO lock-up expiration and excitement for its upcoming...
🟢 Generate Biomedicines is trading 11.71% up today as biotech ETF XBI rises
Generate Biomedicines is trading at $19.80, up 11.71%, primarily on biotech-sector momentum. - The stock rose 9.93% on August 24, 2026, marking its second...
🟢 Generate Biomedicines is trading 4.5% up today amid biotech-sector momentum
Generate Biomedicines is trading 4.5% up now at $18.52, with the move appearing mainly supported by biotechnology-sector momentum rather than a confirmed...
🟢 Generate Biomedicines is trading 10.83% up today without a confirmed company-specific catalyst
Generate Biomedicines is trading 10.83% up now at $17.86, with no confirmed company-specific catalyst on August 24, 2026. - Its latest identifiable company...
🟢 Generate Biomedicines is trading 4.58% up today with no clear catalyst identified
Generate Biomedicines is trading 4.58% higher at $16.86, with no clear catalyst identified. - No new company-specific announcement, analyst action, or other...
🔴 Generate Biomedicines falls 4.2% — Biotech Sector Cools Off After Moderna-Sparked Rally
With Biotech (XBI) down 2.5%, this looks like a sector-led move rather than a company-specific surprise. The biotech sector is experiencing a pullback after a...